LifeMD to offer Novo's Ozempic at $499 per month to eligible US cash-paying customers

LifeMD

30/09/2025 13:11

Sept 30 (Reuters) - Telehealth firm LifeMD LFMD.O said on Tuesday it would collaborate with Novo Nordisk NOVOb.CO to offer its diabetes drug Ozempic at $499 per month to eligible U.S. patients, including those who are insured and whose plans do not cover it.

 (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shilpi Majumdar)

 ((Padmanabhan.Ananthan@thomsonreuters.com;))